162808-62-0 Categories: , ,
  • # LGM Pharma is a Caspofungin CAS# 162808-62-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Caspofungin
  • CAS #: 162808-62-0
  • Mode of Action:

    Caspofungin inhibits the synthesis of beta-(1, 3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. beta-(1, 3)-D-glucan is not present in mammalian cells. The primary target is beta-(1, 3)-glucan synthase.

  • Pharmacodynamics:

    Caspofungin is an antifungal drug, and belongs to a new class termed the echinocandins. It is used to treat Aspergillus and Candida infection, and works by inhibiting cell wall synthesis. Antifungals in the echinocandin class inhibit the synthesis of glucan in the cell wall, probably via the enzyme 1, 3-beta glucan synthase. There is a potential for resistance development to occur, however in vitro resistance development to Caspofungin by Aspergillus species has not been studied.

  • Metabolism:

    Metabolized slowly by hydrolysis and N-acetylation

  • Toxicity:

    Side effects include rash, swelling, and nausea (rare)

  • ATC: J02AX04
  • PubChem: 468682
  • DrugBank: APRD00199
  • Formula: C52-H88-N10-O15
  • Molecular Mass: 1093.32
  • Synonyms: (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide, Cancidas, Caspofungin, HSDB 7476, L 743,872, L 743872, MK 0991, UNII-F0XDI6ZL63
  • SMILES: C(CN)[C@H]([C@@H]1NC(=O)[C@@H]([C@H](O)[C@H](c2ccc(cc2)O)O)NC([C@H]2N(C([C@@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)C[C@H]([C@@H](NC([C@@H]3[C@H](CCN3C1=O)O)=O)NCCN)O)=O)C[C@@H](C2)O)=O)O
  • AHFS Code: 08:14.2
  • General Reference:


    1. Letscher-Bru, Valérie, and Raoul Herbrecht. 2003. Caspofungin: the first representative of a new antifungal class. Journal of Antimicrobial Chemotherapy 51, no. 3 (March 1): 513 -521. doi:10.1093/jac/dkg117.
    2. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. Epub 2009 Sep 1. Pubmed
    3. Morrison VA: Caspofungin: an overview. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. Pubmed
    4. McCormack PL, Perry CM: Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14):2049-68. Pubmed
    5. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. Pubmed
    6. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service